^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

Published date:
09/14/2020
Excerpt:
...advanced NSCLC patients before dabrafenib and trametinib treatment were included...The two patients with a concurrent IDH1 p.(R132C) mutation had a complete response with a PFS of 32 months and an ongoing response of 12 months.